Bulgaria · Delayed Price · Currency is BGN · Price in EUR Sopharma AD Statistics
Total Valuation
Sopharma AD has a market cap or net worth of BGN 1.91 billion. The enterprise value is 2.47 billion.
| Market Cap | 1.91B |
| Enterprise Value | 2.47B |
Important Dates
The next confirmed earnings date is Thursday, July 30, 2026.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | Jul 9, 2026 |
Share Statistics
Sopharma AD has 528.43 million shares outstanding. The number of shares has decreased by -31.67% in one year.
| Current Share Class | 528.43M |
| Shares Outstanding | 528.43M |
| Shares Change (YoY) | -31.67% |
| Shares Change (QoQ) | -24.90% |
| Owned by Insiders (%) | 10.00% |
| Owned by Institutions (%) | 0.29% |
| Float | 168.42M |
Valuation Ratios
The trailing PE ratio is 8.25.
| PE Ratio | 8.25 |
| Forward PE | n/a |
| PS Ratio | 0.71 |
| PB Ratio | 1.85 |
| P/TBV Ratio | 2.53 |
| P/FCF Ratio | 51.32 |
| P/OCF Ratio | 23.40 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.53, with an EV/FCF ratio of 66.24.
| EV / Earnings | 15.94 |
| EV / Sales | 0.93 |
| EV / EBITDA | 9.53 |
| EV / EBIT | 13.60 |
| EV / FCF | 66.24 |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.55.
| Current Ratio | 1.38 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | 2.53 |
| Debt / FCF | 15.33 |
| Interest Coverage | 6.73 |
Financial Efficiency
Return on equity (ROE) is 16.96% and return on invested capital (ROIC) is 8.88%.
| Return on Equity (ROE) | 16.96% |
| Return on Assets (ROA) | 4.64% |
| Return on Invested Capital (ROIC) | 8.88% |
| Return on Capital Employed (ROCE) | 11.58% |
| Weighted Average Cost of Capital (WACC) | 4.54% |
| Revenue Per Employee | 446,855 |
| Profits Per Employee | 25,778 |
| Employee Count | 6,005 |
| Asset Turnover | 1.35 |
| Inventory Turnover | 4.21 |
Taxes
In the past 12 months, Sopharma AD has paid 13.51 million in taxes.
| Income Tax | 13.51M |
| Effective Tax Rate | 7.72% |
Stock Price Statistics
The stock price has increased by +55.74% in the last 52 weeks. The beta is 0.11, so Sopharma AD's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | +55.74% |
| 50-Day Moving Average | 1.89 |
| 200-Day Moving Average | 1.68 |
| Relative Strength Index (RSI) | 45.92 |
| Average Volume (20 Days) | 404,209 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sopharma AD had revenue of BGN 2.68 billion and earned 154.80 million in profits. Earnings per share was 0.44.
| Revenue | 2.68B |
| Gross Profit | 655.14M |
| Operating Income | 147.21M |
| Pretax Income | 175.11M |
| Net Income | 154.80M |
| EBITDA | 219.28M |
| EBIT | 147.21M |
| Earnings Per Share (EPS) | 0.44 |
Balance Sheet
The company has 42.51 million in cash and 570.97 million in debt, with a net cash position of -528.47 million or -1.00 per share.
| Cash & Cash Equivalents | 42.51M |
| Total Debt | 570.97M |
| Net Cash | -528.47M |
| Net Cash Per Share | -1.00 |
| Equity (Book Value) | 1.03B |
| Book Value Per Share | 1.90 |
| Working Capital | 297.08M |
Cash Flow
In the last 12 months, operating cash flow was 81.66 million and capital expenditures -44.43 million, giving a free cash flow of 37.24 million.
| Operating Cash Flow | 81.66M |
| Capital Expenditures | -44.43M |
| Depreciation & Amortization | 73.45M |
| Net Borrowing | 1.58M |
| Free Cash Flow | 37.24M |
| FCF Per Share | 0.07 |
Margins
Gross margin is 24.41%, with operating and profit margins of 5.49% and 5.77%.
| Gross Margin | 24.41% |
| Operating Margin | 5.49% |
| Pretax Margin | 6.53% |
| Profit Margin | 5.77% |
| EBITDA Margin | 8.17% |
| EBIT Margin | 5.49% |
| FCF Margin | 1.39% |
Dividends & Yields
This stock pays an annual dividend of 0.06, which amounts to a dividend yield of 1.55%.
| Dividend Per Share | 0.06 |
| Dividend Yield | 1.55% |
| Dividend Growth (YoY) | 80.70% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 28.47% |
| Buyback Yield | 31.67% |
| Shareholder Yield | 33.21% |
| Earnings Yield | 8.10% |
| FCF Yield | 1.95% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 10, 2025. It was a forward split with a ratio of 3.
| Last Split Date | Jul 10, 2025 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Sopharma AD has an Altman Z-Score of 2.83 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.83 |
| Piotroski F-Score | 7 |